Equivalent of Form PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
Intl. Filing Date	March 9, 2005
First Named Inventor	PATRICK, Guy Michael
Art Unit	*To Be Assigned*
Examiner Name	*To Be Assigned*
Attorney Docket Number	2451.0130000/BJD/GER

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US1	2,934,556	04/26/1960	Hoffmann *et al.*	
	US2	4,499,082	02/12/1985	Shenvi *et al.*	
	US3	4,701,545	10/20/1987	Matteson *et al.*	
	US4	4,927,809	05/22/1990	Stüber	
	US5	4,935,493	06/19/1990	Bachovchin *et al.*	
	US6	4,963,655	10/16/1990	Kinder *et al.*	
	US7	5,169,841	12/08/1992	Kleeman *et al.*	
	US8	5,187,157	02/16/1993	Kettner *et al.*	
	US9	5,444,049	08/22/1995	de Nanteuil *et al.*	
	US10	5,462,964	10/31/1995	Fevig *et al.*	
	US11	5,563,127	10/08/1996	Amparo *et al.*	
	US12	5,574,014	11/12/1996	Claeson *et al.*	
	US13	5,585,360	12/17/1996	de Nanteuil *et al.*	
	US14	5,596,123	01/21/1997	Elgendy *et al.*	
	US15	5,639,739	06/17/1997	Dominguez *et al.*	
	US16	5,658,885	08/19/1997	Lee *et al.*	
	US17	5,681,978	10/28/1997	Matteson *et al.*	
	US18	5,731,439	03/24/1998	Carini *et al.*	
	US19	5,780,454	06/14/1998	Adams *et al.*	
	US20	5,814,622	09/29/1998	de Nanteuil *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
	FP1	WO 89/09612 A1	10/19/1989	Corvas, Inc.	
	FP2	EP 0 471 651 A2	02/19/1992	Sandoz Ltd.; Sandoz-Patent-GmbH; Sandoz-Erfindungen Verwaltungsgeselischaf m.b.H.	
	FP3	WO 92/07869 A1	05/14/1992	Thrombosis Res. Institute; Kakkar *et al.*	
	FP4	EP 0 599 633 A1	06/01/1994	Thrombosis Research Institute	
	FP5	WO 94/21668 A1	09/29/1994	The Du Point Merck Pharmaceutical Co.	
	FP6	WO 94/21650 A1	09/29/1994	The Du Point Merck Pharmaceutical Co.	
	FP7	WO 94/25049 A1	11/10/1994	The Du Point Merck Pharmaceutical Co.	
	FP8	WO 95/09858 A1	04/13/1995	The Du Point Merck Pharmaceutical Co.	
	FP9	WO 95/09859 A1	04/13/1995	The Du Point Merck Pharmaceutical Co.	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
Intl. Filing Date	March 9, 2005
First Named Inventor	PATRICK, Guy Michael
Art Unit	*To Be Assigned*
Examiner Name	*To Be Assigned*
Attorney Docket Number	2451.0130000/BJD/GER

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US20	6,066,730	05/23/2000	Adams *et al.*	
	US21	6,083,903	07/04/2000	Adams *et al.*	
	US22	6,114,308	09/05/2000	Claeson *et al.*	
	US24	6,297,217 B1	10/02/2001	Adams *et al.*	
	US25	6,313,096 B1	11/06/2001	Claeson *et al.*	
	US26	6,417,174 B1	07/09/2002	Shoichet *et al.*	
	US27	6,465,433 B1	10/15/2002	Adams *et al.*	
	US28	6,617,317 B1	09/09/2003	Adams *et al.*	
	US29	6,699,835 B2	03/02/2004	Plamondon *et al.*	
	US30	6,713,446 B2	03/30/2004	Gupta	
	US31	6,747,150 B2	06/08/2004	Adams *et al.*	
	US32	7,112,572 B2	09/26/2006	Deadman *et al.*	
	US33	7,112,590 B2	09/26/2006	Kikelj *et al.*	
	US34	2004/0138175 A1	07/15/2004	Madge *et al.*	
	US35	2005/0119226 A1	06/02/2005	Walter *et al.*	
	US36	2005/0176651 A1	08/11/2005	Madge *et al.*	
	US37	2005/0282757 A1	12/22/2005	Combe-Marzelle *et al.*	
	US38	2005/0288253 A1	12/29/2005	Madge *et al.*	
	US39	2006/0084592 A1	04/20/2006	Boucher	
	US40	2006/0172978 A1	08/03/2006	Russell *et al.*	
	US41	2006/0172920 A1	08/03/2006	Scully *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
	FP10	WO 95/09634 A1	04/13/1995	The Du Point Merck Pharmaceutical Co.	
	FP11	WO 96/12499 A1	02/05/1996	The Du Point Merck Pharmaceutical Co.	
	FP12	WO 96/13266 A1	05/09/1996	Proscript, Inc.	
	FP13	WO 96/20689 A2	07/11/1996	The Du Point Merck Pharmaceutical Co.	
	FP14	WO 97/05161 A1	02/13/1997	Sandoz-Patent-GmbH; Sandoz-Erfindungen Verwaltungsgesellschaft Mbh; Wienand, A.	
	FP15	WO 98/00443 A1	01/08/1998	Thrombosis Research Institute; Deadman *et al.*	
	FP16	WO 98/31688 A1	07/23/1998	Adir et Compagnie; Cordi *et al.*	Abs
	FP17	WO 99/26652 A1	06/03/1999	Danbiosyst UK Ltd.; Watts *et al.*	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08A (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 3

Complete if Known	
Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
Intl. Filing Date	March 9, 2005
First Named Inventor	PATRICK, Guy Michael
Art Unit	*To Be Assigned*
Examiner Name	*To Be Assigned*
Attorney Docket Number	2451.0130000/BJD/GER

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (If Known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US42	2006/0229257 A1	10/12/2006	Deadman *et al.*	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] Number[4] Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T[6]
	FP18	WO 00/41715 A1	06/20/2000	Astranzeneca Ab, Frager G.	
	FP19	WO 00/35904 A1	06/22/2000	Northwestern Univ., Universita Degli Studi Di Modena E Reggio Emilia; Shoichet *et al.*	
	FP20	WO 00/35905 A1	06/22/2000	Northwestern Univ., Universita Degli Studi Di Modena E Reggio Emilia; Shoichet *et al.*	
	FP21	WO 01/02424 A2	01/11/2001	The Du Point Merck Pharmaceutical Co.	
	FP22	WO 01/41796 A1	06/14/2001	Astrazeneca Ab; Mattsson, C.	
	FP23	WO 02/36157 A1	05/10/2002	Astrazeneca Ab; Gustafsson, D.	
	FP24	WO 02/059130 A1	08/01/2002	The United States of America, Secretary, Dept. of Health and Human Services	
	FP25	WO 02/059131 A1	08/01/2002	Milennium Pharmac, Inc.; Plamondon *et al.*	
	FP26	WO 2004/022070 A1	03/18/2004	Trigen Ltd.	
	FP27	WO 2004/022071 A1	03/18/2004	Trigen Ltd.	
	FP28	WO 2004/022072 A1	03/18/2004	Trigen Ltd.	
	FP29	EP 1 466 916 A1	10/13/2004	Trigen Ltd.	
	FP30	EP 1 466 917 A1	10/13/2004	Trigen Ltd.	
	FP31	WO 2005/084686 A2	09/15/2005	Trigen Ltd., Combe-Marzelle *et al.*	

728676v1

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 8

Complete if Known	
Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
Intl. Filing Date	March 9, 2005
First Named Inventor	PATRICK, Guy Michael
Art Unit	*To Be Assigned*
Examiner Name	*To Be Assigned*
Attorney Docket Number	2451.0130000/BJD/GER

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T[2]
	NPL1	Bastin, R.J., *et al.*, "Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities," *Org. Proc. Res. Devel.* *4*:427-435, American Chemical Society and The Royal Society of Chemistry (2000)	
	NPL2	Berge, S.M., *et al.*, "Pharmaceutical Salts," *J. Pharm. Sci.* *66*:1-19, Wiley (1977)	
	NPL3	Brikh, A., and Morin,C., "Boronated thiophenols: a preparation of 4-meracaptophenylboronic acid and derivaties," *J. Organometallic Chem.* *581*:82-86 (1999)	
	NPL4	Carr, J.A., and Silverman, N., "The heparin-protamine interaction," *J. Cardiovasc. Surg.* *40*:659-666, Minerva Medica (1999)	
	NPL5	Chahwala, S.B., *et al.*, "TRI 50, a Potent and Selective Orally Active Direct Thrombin Inhibitor," *Blood* *102*:814a, American Society of Hematology (2003)	
	NPL6	Claeson, G., "Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system," *Blood Coagul. Fibrinolysis* *5*:411-436, Rapid Communications of Oxford Ltd. (1994)	
	NPL7	Claeson, G., *et al.*, "Benzyloxycarbonyl-D-Phe-Pro-methoxypropylboroglycine: a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position," *Biochem J.* 290:309-312, Portland Press (1993)	
	NPL8	Claeson, G., *et al.*, "Design of Novel Types of Thrombin Inhibitors Based on Modified D-PHE-PRO-ARG Sequenes," in *The Design of Synthetic Inhibitors of Thrombin*, Claeson G., *et al.*, eds., Plenum Press, New York, NY pp. 83-89 (1993)	
	NPL9	Claeson, G., *et al.*, "Novel peptide mimetics as highly efficient inhibitors of thrombin based on modified D-Phe-Pro-Arg sequences," in *Peptide, Chemistry and Biology*, Smith, J.A., and River, J.E., *eds.*, Escom: Linden, pp. 824-825 (1992)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
				Intl. Filing Date	March 9, 2005
				First Named Inventor	PATRICK, Guy Michael
				Art Unit	*To Be Assigned*
				Examiner Name	*To Be Assigned*
Sheet	2	of	8	Attorney Docket Number	2451.0130000/BJD/GER

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
	NPL10	Claeson, G., *et al.*, "New Peptide Boronic Acid Inhibitor of Thrombin," *Thromb. Haemost. 65*:1289, Schattauer (1991)	
	NPL11	Coburn, C.A., "Small-molecule direct thrombin inhibitors: 1997-2000," *Exp. Opin. Ther. Patents 11*:721-738, Ashley Publications Ltd. (2001)	
	NPL12	Contreras, R., *et al.*, "The N-B Coordination in Hindered Cyclic-Thexylboronic Esters Derived from Diethanolamines," *J. Organomettalic Chem. 246*:213-217, Elsevier Sequoia S.A. (1983)	
	NPL13	Davies, A.G., *et al.*, "Peroxides of Elements other than Carbon. Part XII. The Autoxidation of Optically Active 1-Phenylethylboronic Acid," *J. Chem. Soc. B*: 17-22, Chemical Society (1967)	
	NPL14	Davies, G., "Changing the Salt, Changing the Drug," *Pharmaceut. J.* 266:322-323, Wiley (2001)	
	NPL15	Deadman, J., *et al.*, "Structure/Function Aspects of Neutral P1 Residue Peptide Inhibitors of Thrombin," *J. Enzym. Inhib. 9*:29-41, Harwood Academic Publishers GmbH (1995)	
	NPL16	Deadman, J.J., *et al.*, "Characterization of a Class of Peptide Boronates with Neutral P1 Side Chains as Highly Selective Inhibitors of Thrombin," *J. Med. Chem. 38*:1511-1522, American Chemical Society (1995)	
	NPL17	Elgendy, S., *et al.*, "Facile Routes to 1-Halo-1-Alkyl Boronic Esters as Precursors for Novel Thrombin Inhibitors," *Tetrahedron 50*:3803-3812, Elsevier Science Ltd. (1994)	
	NPL18	Elgendy, S., *et al.*, "New Peptide Boronic Acid Inhibitors of Thrombin," *Tetrahedron Lett. 33*:4209-4212, Pregamon Press Ltd. (1992)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 8

Complete if Known	
Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
Intl. Filing Date	March 9, 2005
First Named Inventor	PATRICK, Guy Michael
Art Unit	*To Be Assigned*
Examiner Name	*To Be Assigned*
Attorney Docket Number	2451.0130000/BJD/GER

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
	NPL19	Elgendy, S., *et al.*, "New Peptide Boronic Acid Inhibitors of Thrombin," in *The Design of Synthetic Inhibitors of Thrombin* , G. Claeson, *et al.*, eds., Plenum Press, New York, NY pp. 173-178 (1993)	
	NPL20	Elgendy, S., *et al.*, "Design of a novel class of bifunctional thrombin inhibitors, synthesised by the first application of peptide boronates in solid phase chemistry," *Tetrahedron Lett. 38*:3305-3308, Elsevier Science Ltd. (1997)	
	NPL21	Elgendy, S., *et al.*, "Peptide Amino Boronic Acids as Thrombin Inhibitors. Effects on Ki and Hypotensive Side-Effects of the Modifications of the Boronic Acid Side Chain," *Thromb. Haemost. 65*:775, Schattauer (1991)	
	NPL22	Esmail, A.F., *et al.*, "Antithrombotic and Anticoagulant Properties of Novel Peptide Boronic and Thrombin Inhibitors: Comparison with Heparin and Hirudin," *Thromb. Haemost. 73*: 1318, Schattauer (1995)	
	NPL23	Esmail, A.F., *et al.*, "Effect of Triban a novel thrombin inhibitor on platelet procoagulant activity in vitro and SK induced thrombolysis In vivo," *Thromb. Haemost. 5*:498-499, Schattauer (1997)	
	NPL24	Esmail, A.F., *et al.*, "Comparison of antithrombotic properties of Triban, hirudin, heparin and aspirin in a new dynamic model of venous thrombosis," *Thromb. Haemost. 5*:91-92, Schattauer (1997)	
	NPL25	Gerrard, D., *et al.*, "Prevention of Thrombosis in a Pig Coronary Model, Comparison of the Efficacy of a Specific Thrombin Inhibitors TRI50b with Aspirin," *Thromb. Haemost. 6*:1307, Schattauer (1995)	
	NPL26	Gustafsson, D., *et al.*, "The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects," *Thromb. Res. 101*:171-181, Elsevier Science Ltd. (2001)	
	NPL27	Hsiao, G.K., and Hangauer, D.G., "A Facile Synthesis of *tert*-Butyl 2-[(Benzyloxycarbonyl)amino]-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)propionate: An Orthogonally Protected Boronic Acid Analog of Aspartic Acid," *Synthesis 7*:1043-1046, Thieme (1997)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
				Intl. Filing Date	March 9, 2005
				First Named Inventor	PATRICK, Guy Michael
				Art Unit	*To Be Assigned*
				Examiner Name	*To Be Assigned*
Sheet	4	of	8	Attorney Docket Number	2451.0130000/BJD/GER

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
	NPL28	Katz, B.A., *et al.*, "Episelection: Novel K_i ~ Nanomolar Inhibitors of Serine Proteases Selected by Binding or Chemistry on an Enzyme Surface," *Biochemistry 34*:8264-8280, American Chemical Society (1995)	
	NPL29	Kettner, C.A., and Shenvi, A.B. ,"Inhibition of the Serine Proteases Leukocyte Elastase, Panacreatic Elastase, Cathepsin G, and Chymotrypsin by Peptide Boronic Acids," *J. Biol. Chem. 259*:15106-15114, The American Society of Biological Chemists, Inc. (1984)	
	NPL30	Kettner, C., *et al.*, "The Selective Inhibition of Thrombin by Peptides of Boroarginine," *J. Biol. Chem. 265*:18289-18297, The American Society for Biochemistry and Molecular Biology, Inc. (1990)	
	NPL31	Kimmel, S.E., *et al.*, "Mortality and Adverse Events After Protamine Administration in Patients Undergoing Cardiopulmonary Bypass," *Anesth. Analg. 94*:1402-1408, The International Anesthesia Research Society (2002)	
	NPL32	Kimmel, S.E., *et al.*, "Adverse Events after Protamine Administration in Patients Undergoing Cardiopulmonary Bypass: Risks and Predictors of Under-Reporting," *J. Clin. Epidemiol. 51*:1-10, Elsevier Science Inc. (1998)	
	NPL33	M.F. Lappert, "Organic Compounds of Boron," *Chem. Rev. 56*:959-1064, American Chemical Society (1956)	
	NPL34	Martinchonok, V., and Jones, B.J., "Probing the Specificity of the Serine Proteases Subtilisin Carlsberg and α-Chymotrypsin with Enantiomeric 1-Acetamido Boronic Acids. An Unexpected Reversal of the Normal "L"-Stereoselectivity Preference," *J. Am. Chem. Soc. 118*:950-958, American Chemical Society (1996)	
	NPL35	Martichonok, V., and Jones, J.B., "Cysteine Proteases such as Papain are not Inhibited by Substrate Analogue Peptidyl Boronic Acids," *Bioorg. Med. Chem. 5*:679-684, Elsevier Science Ltd. (1997)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
				Intl. Filing Date	March 9, 2005
				First Named Inventor	PATRICK, Guy Michael
				Art Unit	*To Be Assigned*
				Examiner Name	*To Be Assigned*
Sheet	5	of	8	Attorney Docket Number	2451.0130000/BJD/GER

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
	NPL36	Matteson, D.S., "α-Halo Boronic Esters: Intermediates for Stereodirected Synthesis," *Chem. Rev. 89*:1535-1551, American Chemical Society (1989)	
	NPL37	Matteson, D.S., and Man, H.-W., "Hydrolysis of Substituted 1,3,2-Dioxaborolanes and an Asymmetric Synthesis of a Differentially Protected syn,syn-3-Methyl-2,4-hexanediol," *J. Org. Chem. 61*:6047-6051, American Chemical Society (1996)	
	NPL38	Mauney, M.C., *et al.*, "Stroke rate is markedly reduced after carotid endarterectomy by avoidance of protamine," *J. Vasc. Surg. 22*:264-270, Mosby-Year Book, Inc. (1995)	
	NPL39	McGregor, J.L., "Current Perspective on Antithrombin Drugs," *Pathophysiol. Haemost. Thromb. 32(Suppl. 3)*:29-35, S. Karger AG, Basel (2002)	
	NPL40	Metternich, R., *et al.*, "In Vitro and In Vivo Evaluation of Neutral Boron Containing Thrombin Inhibitors," *Naunyn Schmiedebergs Arch. Pharmacol. 97*:387, Springer Verlag (1992)	
	NPL41	Philipp, M., *et al.*, "ph-Dependent Binding Constants for the Inhibition of Thrombin by Transition State Analogs,"in *The Design of Synthetic Inhibitors of Thrombin*, Claeson, G., *et al.*, eds., Plenum Press, New York, NY pp. 67-77 (1993)	
	NPL42	Rewinkel, J.B.M., and Adang, A.E.P., "Strategies and Progress Towards the Ideal Orally Active Thrombin Inhibitor," *Curr. Pharma. Design 5*:1043-1075, Benthum Science Publishers B.V. (1999)	
	NPL43	Russell, V.P., *et al.*, "A Specific Neutralizing Agent for the Direct Thrombin Inhibitor TRI 50," *Blood 102*:814a, American Society of Hematology (2003)	
	NPL44	Sanderson, P.E.J., and Naylor-Olsen, A.M., "Thrombin Inhibitor Design," *Curr. Med. Chem. 5*:299-304, Bentham Science Publishers B.V. (1998)	
	NPL45	Satioh, H., and Aungst, B.J., "Improvement of the Intestinal Absorption of a Peptidomimetic, Boronic Acid Thrombin Inhibitor Possibly Utilizing the Oligopeptide Transporter," *Pharma. Res. 16*:1786-1789, Plenum Publishing Corporation (1999)	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
				Intl. Filing Date	March 9, 2005
				First Named Inventor	PATRICK, Guy Michael
				Art Unit	*To Be Assigned*
				Examiner Name	*To Be Assigned*
Sheet	6	of	8	Attorney Docket Number	2451.0130000/BJD/GER

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
	NPL46	Skordalakes, E., *et al.*, "Bifunctional Peptide Boronate Inhibitors of Thrombin: Crystallographic Analysis of Inhibition Enhanced by Linkage to an Exosite 1 Binding Peptide," *Biochem. 37*:14420-14427, American Chemical Society (1998)	
	NPL47	Skordalakes, E., *et al.*, "Crystallographic Structures of Human α-Thrombin Complexed to Peptide Boronic Acids Lacking a Positive Charge at P1. Evidence of Novel Interactions," *J. Am. Chem. Soc. 119*:9935-9936, American Chemical Society (1997)	
	NPL48	Snyder, H.R., *et al.*, "Organoboron Compounds, and the Study of Reaction Mechanisms. Primary Aliphatic Boronic Acids," *J. Am. Chem. Soc. 60*:105-111, American Chemical Society (1933)	
	NPL49	Snyder, H.R., *et al.*, "Aryl Boronic Acids. II. Aryl Boronic Anhydrides and their Amine Complexes," *J. Am. Chem. Soc. 80*:3611-3615, American Chemical Society (1958)	
	NPL50	Spencer, J., *et al.*, "Synthesis of *ortho*-modified mercapto- and piperazino-methyl-phenylboronic acid derivatives," *Tetrahedron 58*:1551-1556, Elsevier Science Ltd. (2002)	
	NPL51	Steinmetzer, R., *et al.*, "Advances in the development of thrombin inhibitors," *Expert Opin. Investig. Drugs 10*:845-864, Ashley Publications Ltd. (2001)	
	NPL52	Tapparelli, C., *et al.*, "*In Vitro* and *In Vivo* Characterization of a Neutral Boron-containing Thrombin Inhibitor," *J. Biol. Chem. 258*:4734-4741, The American Society for Biochemistry and Molecular Biology, Inc. (1993)	
	NPL53	Tapparelli, C., *et al.*, "Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile," *Trends Pharmacol. Sci. 14*:366-375, Elsevier Science Publishers Ltd. (1993)	
	NPL54	Trigen Limited, "Looking for a career in Biotechnology," poster exhibited at the *XVIITH International Symposium on Medicinal Chemistry*, Barcelona, Spain, September 5, 2002	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 7 of 8

Complete if Known	
Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
Intl. Filing Date	March 9, 2005
First Named Inventor	PATRICK, Guy Michael
Art Unit	*To Be Assigned*
Examiner Name	*To Be Assigned*
Attorney Docket Number	2451.0130000/BJD/GER

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
	NPL55	Trigen Limited, "TRI 50b Non Confidential Information", pp. 1-12, July 2002	
	NPL56	Tripathy, P.B., and Matteson, D.S., "Asymmetric Synthesis of the Four Stereoisomers of 4-Methyl-3-heptanol via Boronic Esters: Sequential Double Stereodifferentiation Leads to Very High Purity," *Synthesis 1990*:200-206, Thieme (1990)	
	NPL57	von Matt, A., *et al.*, "Selective Boron-Containing Thrombin Inhibitors X-ray Analysis Reveals Surprising Binding Mode," *Bioorg. Med. Chem. 8*:2291-2303, Elsevier Science Ltd. (2000)	
	NPL58	Wityak, J., *et al.*, "Synthesis of Thrombin Inhibitor DuP 714," *J. Org. Chem. 60*:3717-3722, American Chemical Society (1995)	
	NPL59	Wu, S., *et al.*, "Degradation Pathways of a Peptide Boronic Acid Derivative, 2-Pyz-(CO)-Phe-Leu-$B(OH)_2$," *J. Pharmaceut. Sci. 89*:758-765, Wiley-Liss, Inc. and the American Pharmaceutical Association (2000)	
	NPL60	Yang, C.Y., *et al.*, "Intestinal Peptide Transport Systems and Oral Drug Availability," *Pharamaceut. Res. 16*:1331-1343, Plenum Publishing Corp. (1999)	
	NPL61	Yang, W., *et al.*, "Boronic Acid Compounds as Potential Pharmaceutical Agents," *Med. Res. Rev. 23*:346-368, Wiley Periodicals, Inc. (2003)	
	NPL62	Zavoico, G.B., "Emerging Cardiovascular Therapeutics," *Cardiovas. Drug Rev. 21*:246-253, Neva Press (2003)	
	NPL63	Office Action mailed August 9, 2007 in United States Patent Application No. 10/937,181, Walter, A., *et al.*, filed September 9, 2004	

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Equivalent of Form PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				***Complete if Known***	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT *(Use as many sheets as necessary)*				Application Number	10/591,962 (Natl. Phase of PCT/GB2005/000907)
				Intl. Filing Date	March 9, 2005
				First Named Inventor	PATRICK, Guy Michael
				Art Unit	*To Be Assigned*
				Examiner Name	*To Be Assigned*
Sheet	8	of	8	Attorney Docket Number	2451.0130000/BJD/GER

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T[2]
	NPL64	Office Action mailed February 5, 2007 in United States Patent Application No. 10/659,178, Madge, D.J., *et al.*, filed September 9, 2003	
	NPL65	Office Action mailed May 23, 2007 in United States Patent Application No. 10/659,178, Madge, D.J., *et al.*, filed September 9, 2003	
	NPL66	Office Action mailed July 25, 2006 in United States Patent Application No. 10/658,971, Madge, D.J., *et al.*, filed September 9, 2003	
	NPL67	Office Action mailed January 25, 2007 in United States Patent Application No. 10/658,971, Madge, D.J., *et al.*, filed September 9, 2003	
	NPL68	Advisory Action mailed May 10, 2007 in United States Patent Application No. 10/658,971, Madge, D.J., *et al.*, filed September 9, 2003	
	NPL69	Office Action mailed November 29, 2007 in United States Patent Application No. 11/077,620, Boucher, O.V.A. *et al.*, filed March 9, 2005	
	NPL70	Office Action mailed November 9, 2007 in United States Patent Application No. 11/077,620, Boucher, O.V.A. *et al.*, filed March 9, 2005	
	NPL71	Office Action mailed November 9, 2007 in United States Patent Application No. 11/078,097, Combe-Marzelle, S.M. *et al.*, filed March 9, 2005	
	NPL72	Office Action mailed September 19, 2007 in United States Patent Application No. 10/937,854, Madge, D.J. *et al.*, filed September 8, 2004	

728880v1

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.